このエントリーをはてなブックマークに追加
ID 37803
file
creator
Marubayashi, Seiji
Yamamoto, Hiroyuki
Shibata, Satoshi
Fudaba, Yasuhiro
Fukuma, Kazuyuki
Okada, Kazuro
Ikeda, Masahiro
Maeda, Takashi
Oshiro, Yoshio
Dohi, Kiyohiko
subject
Erythrocytosis
Renal transplantation
Angiotensin converting enzyme inhibitor
NDC
Medical sciences
abstract
Post-transplant erythrocytosis (PTE) is increasingly recognized as a complication of kidney transplantation. In this study we report the effect of the angiotesin-converting enzyme (ACE) inhibitor enalapril on hematocrit (Ht) and erythropoietin in four patients with PTE. Four renal allograft recipients with Ht greater than 51 % were studied. Treatment was initiated with enalapril administered orally at a dose of 2.5 mg/day. All the patients had an increase of hemoglobin (Hb) (17.7 ± 0.64 g/dl), Ht (54.5 ± 1.29 %) and red blood cell count (REC) (584 ± 19.2 × 10⁴/μl). All patients responded to enalapril in 8 weeks with a significant decrease of Hb, Ht, and REC. In one patient, the downward trend was more rapid and sustained, and treatment had to be discontinued to prevent the development of anemia. Serum erythropoietin showed normal in all four patients and remained unchanged during the study, even after discontinuation of enalapril treatment. Serum creatinine remained relatively stable throughout the study. These results suggest that PTE may not be dependent upon circulating erythropoietin and that enalapril treatment may be an effective treatment of PTE without renal dysfunction.
journal title
Hiroshima Journal of Medical Sciences
volume
Volume 47
issue
Issue 3
start page
121
end page
124
date of issued
1998-09
publisher
Hiroshima University Medical Press
issn
0018-2052
ncid
language
eng
nii type
Departmental Bulletin Paper
HU type
Departmental Bulletin Papers
DCMI type
text
format
application/pdf
text version
publisher
department
Graduate School of Biomedical Science
他の一覧